Is AVTR a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Avantor (AVTR) rests on Revival transformation program: Management launched a company-wide "Revival" program to cut costs, simplify the organization, and improve commercial execution. Revenue (FY2025) is ~$6.55B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. Whether AVTR is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Avantor, Inc. is a global provider of high-purity materials, consumables, equipment, and specialized services used across biopharma, healthcare, education, government, and advanced technology markets. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company sells everything from high-purity chemicals and reagents, lab supplies, and customized excipients to single-use assemblies, chromatography resins, and fluid handling systems. It reorganized around two reporting segments (Laboratory Solutions and a Bioscience and Medtech Products grouping), and a large share of its revenue is recurring consumables that customers reorder repeatedly, which gives the model a razor-and-blade quality tied to laboratory activity and biologic manufacturing volumes. The investment picture as of July 2026 is dominated by a turnaround. Revenue slipped to roughly $6.55 billion in 2025 and organic sales were still declining modestly in early 2026 as biopharma customers stayed cautious on spending, yet Q1 2026 results beat expectations and the stock jumped, signaling early traction from the company's Revival cost and execution program. Avantor carries meaningful debt (net leverage above 3x adjusted EBITDA), so the equity behaves like a leveraged recovery play: if organic growth and margins inflect, the discounted valuation relative to larger tools peers offers upside, but if end markets stay weak the balance sheet limits room for error.
What's the case for buying AVTR?
1. Revival transformation program
Management launched a company-wide "Revival" program to cut costs, simplify the organization, and improve commercial execution. Q1 2026 results exceeded expectations partly on this self-help, and a new Chief Transformation Officer (Ludovic Brellier, hired from Danaher's Cytiva) was brought in to run the effort. Success here is the central swing factor for margins over the next several years.
2. Recurring consumables and bioprocessing exposure
A large portion of Avantor's sales are repeat-purchase consumables tied to ongoing lab and manufacturing activity rather than one-time capital equipment. Its Bioscience Production exposure (single-use assemblies, chromatography resins, excipients) links it to biologics and vaccine production, a structurally growing end market. This recurring base gives revenue relative stability once destocking and customer caution normalize.
3. End-market normalization
The soft patch across life sciences tools has been driven by post-pandemic inventory destocking and tighter biopharma and academic budgets. As those pressures ease, Avantor is positioned to return to organic growth. Management framed 2026 as a stabilization year, with organic revenue guided to roughly flat to slightly down and improvement expected as comparisons ease.
4. Free cash flow and deleveraging
Avantor generates substantial free cash flow (guided to roughly $500 million to $550 million for 2026), which it is directing toward reducing net leverage from above 3x adjusted EBITDA. Steady debt paydown would lower interest costs and financial risk, improving the equity's risk profile even before any strong top-line acceleration.
What are the risks to AVTR?
Avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. The company carries meaningful leverage (adjusted net leverage above 3x), which amplifies the downside if EBITDA disappoints and constrains flexibility. It reported GAAP net losses tied to write-downs, and the turnaround depends heavily on execution by a leadership team still being reshaped. It also competes against much larger, better-capitalized peers such as Thermo Fisher, and its exposure to biopharma capex, academic funding cycles, and currency swings adds cyclicality. Any renewed destocking or funding cuts in life sciences would pressure results.
How is AVTR valued? (as of July 2026)
Snapshot for AVTR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025): ~$6.55B
- Q1 2026 net sales: ~$1.58B
- Q1 2026 adjusted EBITDA: ~$219M (~13.9% margin)
- 2026 adjusted EPS guide: ~$0.77 to $0.83
- Market cap: ~$5.7B
- Net debt / leverage: ~$3.6B (~3.2x adj. EBITDA)
As of July 2026 Avantor trades at a steep discount to larger life sciences tools peers, reflecting its slower growth, thinner margins, and higher leverage. The valuation embeds skepticism about the turnaround, so the stock tends to react sharply to signs of organic-growth inflection or margin recovery, as seen when shares jumped on the Q1 2026 beat. Figures are approximate and reference reported 2025 and Q1 2026 results.
How do you decide if AVTR is a buy?
Rather than asking whether AVTR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold AVTR indirectly through an index or sector ETF before adding more.
For the full picture, see the AVTR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AVTR against your real portfolio and see your actual exposure before deciding.
The bottom line on AVTR
The bottom line: Avantor's story right now is Revival transformation program, with revenue (fy2025) at ~$6.55B. If you believe that narrative continues, the call is about sizing AVTR sensibly and checking overlap with what you own; if you doubt it (the risk: avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around AVTR with Walnut
Use Avantor as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is AVTR a good stock to buy right now?
+
The case for Avantor right now is Revival transformation program, with revenue (fy2025) at ~$6.55B. If you believe that thesis holds, AVTR is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Avantor do?
+
Avantor, Inc.
What are the main risks of AVTR?
+
Avantor's organic revenue was still declining in early 2026, so the growth recovery remains unproven and could stall if biopharma and academic customers keep spending cautiously. The company carries meaningful leverage (adjusted net leverage above 3x), which amplifies the downside if EBITDA disappoints and constrains flexibility. It reported GAAP net losses tied to write-downs, and the turnaround depends heavily on execution by a leadership team still being reshaped. It also competes against much larger, better-capitalized peers such as Thermo Fisher, and its exposure to biopharma capex, academic funding cycles, and currency swings adds cyclicality. Any renewed destocking or funding cuts in life sciences would pressure results.
What does Avantor do?
+
Avantor supplies mission-critical products and services to life sciences and advanced technology customers, including high-purity chemicals, reagents, lab supplies, excipients, single-use assemblies, chromatography resins, and specialized procurement and manufacturing services. Much of its revenue comes from recurring consumables used in laboratories and biologic production.
Is Avantor profitable?
+
Avantor generates positive adjusted EBITDA and free cash flow, and reported roughly $43 million of net income and about $219 million of adjusted EBITDA in Q1 2026. However, it also reported GAAP net losses in some recent periods tied to write-downs, so profitability depends on which measure you look at.
What is Avantor's Revival program?
+
Revival is a company-wide transformation initiative launched to cut costs, simplify the organization, and improve commercial and operational execution. A dedicated Chief Transformation Officer runs the Revival Management Office, and early results in Q1 2026 suggested the program was gaining traction.
Who are Avantor's main competitors?
+
Avantor competes with much larger life sciences tools companies such as Thermo Fisher Scientific, Danaher, and Agilent, plus bioprocessing and lab specialists like Merck KGaA (MilliporeSigma), Sartorius, and Bio-Rad. It also faces other lab-supply distributors in its channel business.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell AVTR; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.